Literature DB >> 29472359

Usefulness of initial plasma dabigatran concentration to predict rebound after reversal.

Nicolas Gendron1,2,3, Juliette Gay1,2, Marine Lemoine4, Pascale Gaussem1,2,3, Agnès Lillo-Le-Louet4, David M Smadja5,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29472359      PMCID： PMC5927968          DOI： 10.3324/haematol.2017.183400

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran: comment.

Authors:  A Tripodi
Journal:  J Thromb Haemost       Date:  2017-07-14       Impact factor: 5.824

2.  Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding.

Authors:  Hervé Quintard; Delphine Viard; Milou-Daniel Drici; Caroline Ruetsch; Charles Marc Samama; Carole Ichai
Journal:  Thromb Haemost       Date:  2016-10-13       Impact factor: 5.249

3.  Idarucizumab for dabigatran reversal - Does one dose fit all?

Authors:  Amihai Rottenstreich; Nivin Jahshan; Limor Avraham; Yosef Kalish
Journal:  Thromb Res       Date:  2016-09-13       Impact factor: 3.944

4.  Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.

Authors:  Kaylee K Marino; Raul A Santiago; Richard B Dew; Nancy Berliner; Jean M Connors; Nathan T Connell; John Kevin Tucker
Journal:  Pharmacotherapy       Date:  2016-09-25       Impact factor: 4.705

5.  Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.

Authors:  Charles V Pollack; Paul A Reilly; Joanne van Ryn; John W Eikelboom; Stephan Glund; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Chak-Wah Kam; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Gordon Royle; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Peter Verhamme; Bushi Wang; Laura Young; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2017-07-11       Impact factor: 91.245

6.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

7.  [Management of direct oral anticoagulants for invasive procedures].

Authors:  A Godier; I Gouin-Thibault; N Rosencher; P Albaladejo
Journal:  J Mal Vasc       Date:  2015-03-14

Review 8.  When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.

Authors:  J H Levy; W Ageno; N C Chan; M Crowther; P Verhamme; J I Weitz
Journal:  J Thromb Haemost       Date:  2016-02-17       Impact factor: 5.824

9.  Real-world use of idarucizumab for dabigatran reversal in three cases of serious bleeding.

Authors:  Nicolas Gendron; Anne Laure Feral-Pierssens; Igor Jurcisin; Emmanuelle de Raucourt; Valerie Bouton; Anne Marie Fischer; Camille Lorenceau-Savale; Agnès Lillo-Le Louët; David M Smadja
Journal:  Clin Case Rep       Date:  2017-02-10
View more
  2 in total

1.  Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?

Authors:  Mathias Ströhle; Christopher Rugg; Stefan Schmid; Dietmar Fries; Elgar Oswald
Journal:  Trauma Case Rep       Date:  2021-02-10

Review 2.  Decision-Making Process for the Management of Acute Stroke in Patients on Oral Anticoagulant: From Guidelines to Clinical Routine.

Authors:  Igor Sibon; Mikael Mazighi; Didier Smadja
Journal:  Front Neurol       Date:  2022-01-05       Impact factor: 4.003
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.